Company / R&D per Share
Gossamer Bio, Inc. R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.77
FY2025
5-year range
$0.61 / $2.27
FY2021-FY2025
Trend
+25.0%
vs FY2024
Sector context
#155 of 208
Health Care
What the data says
Gossamer Bio, Inc.'s r&d per share of $0.77 is lower than 75% of companies in the Health Care sector (FY2025). R&D per Share returned to growth in FY2025 after 6 years of decline, reaching $0.77.
Based on SEC 10-K filings.
0.77 in FY2025 with a 5-year CAGR of -20.0%.
Declined from $0.89 to $0.77 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -27.6%
- 5-Year CAGR
- -20.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 208This company $0.77 Sector average $28.82
▼
-97.3% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 25.0% year-over-year.
- Ranks #155 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -9.62 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.77 | +25.0% |
| FY2024 | $0.61 | -30.7% |
| FY2023 | $0.89 | -56.1% |
| FY2022 | $2.02 | -11.2% |
| FY2021 | $2.27 | -3.1% |
| FY2020 | $2.35 | -10.4% |
| FY2019 | $2.62 | -69.2% |
| FY2018 | $8.50 | +8638.0% |
| FY2017 | $0.10 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026